Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 5:22 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 120 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Interferon Gamma Clear all

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: Interferon-gamma 1b; Drug
Lead sponsor: InterMune; Industry
Eligibility: 20 Years to 79 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Aplastic Anemia, Cytopenia, Hypocellular Marrow
Interventions: Emapalumab; Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 0 Years to 25 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2029
U.S. locations: 6
States / cities: New York, New York • Cincinnati, Ohio • Philadelphia, Pennsylvania + 2 more

Conditions: Vitamin D Deficiency, Coronary Artery Disease, Endothelial Dysfunction, Inflammation
Interventions: Ergocalciferol, Sugar pill; Drug · Other
Lead sponsor: Seth I. Sokol, M.D.; Other
Eligibility: 18 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 2
States / cities: The Bronx, New York

Conditions: HIV Infections
Interventions: Zidovudine, Interferon gamma-1b; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1993
U.S. locations: 1
States / cities: New York, New York

Conditions: Pneumonia, Pulmonary Tuberculosis
Interventions: Interferon Gamma; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1994 – 2003
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Adenovirus, Cytomegalovirus Infections, Epstein-Barr Virus Infections
Interventions: Specific T- Lymphocytes; Biological
Lead sponsor: Paul Szabolcs; Other
Eligibility: 1 Month to 65 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: HIV Infections
Interventions: Tumor Necrosis Factor, Interferon gamma-1b; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1990
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Multiple Myeloma, Large B-cell Lymphoma (LBCL)
Interventions: Emapalumab; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 3
States / cities: Brooklyn, New York • Manhattan, New York • Mineola, New York

Conditions: Colorectal Cancer, Hematologic Malignancy, Rectum Cancer, Acute Myeloid Leukemia, Myelodysplastic Syndromes, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Hodgkin Lymphoma, Non Hodgkin Lymphoma, Myeloproliferative Syndrome, Plasma Cell Myeloma, Gastric Cancer, Esophageal Cancer, Esophagus Cancer, Gastric Cancer, Metastatic, Unresectable Esophageal Cancer, Metastatic Esophageal Cancer
Interventions: Vactosertib, Fludarabine Phosphate, Cyclophosphamide, IL-2, Natural Killer Cells; Drug
Lead sponsor: David Wald; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Thrombocytopenia, Hepatitis C, HIV Infections
Interventions: Anti-D; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cancer
Interventions: Autologous Monocytes + ACTIMMUNE + SYLATRON; Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hookworm Infection, Hookworm Disease
Interventions: Na-GST-1/Alhydrogel®, CpG 10104; Biological
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 50 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Acute Leukemia, Myelodysplastic Syndromes
Interventions: Interferon gamma (IFNγ)-primed human bone marrow-derived mesenchymal stromal cells; Drug
Lead sponsor: Edwin Horwitz; Other
Eligibility: 1 Year and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 3
States / cities: Atlanta, Georgia

Conditions: Chronic Granulomatous Disease
Interventions: Administration of drug (Interferon-gamma 1-b) subcutaneously; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 60 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Large B-cell Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B-cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma
Interventions: Emapalumab, Cyclophosphamide, Fludarabine Phosphate, Axicabtagene Ciloleucel, Dexamethasone, Lisocabtagene maraleucel; Drug
Lead sponsor: Marcela V. Maus, M.D.,Ph.D.; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Atypical Mycobacterium Infection
Interventions: Interleukin-12; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2003
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Chronic Hepatitis C
Interventions: Consensus Interferon-Alpha, Interferon Gamma-1b, Ribavirin; Drug
Lead sponsor: InterMune; Industry
Eligibility: 18 Years and older
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Brisbane, California

Conditions: Basal Cell Carcinoma
Interventions: SP-002, Vismodegib; Drug
Lead sponsor: Stamford Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 10
States / cities: Phoenix, Arizona • Boca Raton, Florida • Coral Springs, Florida + 7 more

Conditions: Melanoma (Skin), Unspecified Adult Solid Tumor, Protocol Specific
Interventions: recombinant interferon gamma; Biological
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Metastatic Myxoid Liposarcoma, Metastatic Round Cell Liposarcoma, Metastatic Synovial Sarcoma, Recurrent Mycosis Fungoides and Sezary Syndrome, Refractory Mycosis Fungoides and Sezary Syndrome, Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage II Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage III Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IIIA Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IIIB Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IVA Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IVB Mycosis Fungoides and Sezary Syndrome AJCC v7, Unresectable Synovial Sarcoma
Interventions: Interferon Gamma-1b, Laboratory Biomarker Analysis, Pembrolizumab; Biological · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 12 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 7
States / cities: Palo Alto, California • Miami, Florida • Boston, Massachusetts + 4 more

Conditions: Melanoma (Skin)
Interventions: MART-1 antigen, aldesleukin, gp100 antigen, recombinant CD40-ligand, recombinant interferon gamma, recombinant interleukin-4, sargramostim, therapeutic autologous dendritic cells, therapeutic tumor infiltrating lymphocytes, tyrosinase peptide, Candida albicans skin test reagent; Biological · Radiation
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2006
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Friedreich's Ataxia
Interventions: interferon γ-1b; Drug
Lead sponsor: Amgen; Industry
Eligibility: 11 Years to 27 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 4
States / cities: Los Angeles, California • Gainesville, Florida • Iowa City, Iowa + 1 more

Conditions: Retinal Disease, Macular Disease
Interventions: Interferon gamma-1b; Drug
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV Infections
Interventions: Interferon gamma-1b; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

A Study of the Safety and Clinical Effects of Interferon Gamma-1b in Patients With Idiopathic Pulmonary Fibrosis (IPF)

A Study of Emapalumab for Pediatric Aplastic Anemia

Vitamin D Repletion in Coronary Artery Disease

The Safety and Effectiveness of Injections of Human Recombinant Interferon-gamma in Patients With AIDS Who Have Taken Zidovudine

Interferon Gamma for Drug Resistant Tuberculosis

Anti-viral T-cell Therapy by Gamma Capture

A Study of Tumor Necrosis Factor and Human Interferon-gamma in Patients With AIDS Related Complex

Emapalumab Prophylaxis of Bispecific T-Cell Engagers (BiTEs) Associated CRS and ICANS

Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer

Anti-D for Treating Thrombocytopenia in Adults Infected With Hepatitis C Virus With or Without HIV Co-Infection

Intraperitoneal Infusion of Autologous Monocytes With Sylatron (Peginterferon Alfa-2b) and Actimmune (Interferon Gamma-1b) in Women With Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer

Safety and Immunogenicity Study of Na-GST-1 With or Without CpG

Interferon γ-Primed Mesenchymal Stromal Cells as Prophylaxis for Acute Graft v Host Disease

Effect of IFN-γ on Innate Immune Cells

Emapalumab Prevention of CAR-T Cell Associated Toxicities

Interleukin-12 in the Treatment of Severe Nontuberculous Mycobacterial Infections

CIFN and IFN γ-1b With or Without Ribavirin for Treatment of Chronic Hepatitis C (Nonresponders)

To Assess the Safety and Efficacy of SP-002 with Vismodegib for the Treatment of Locally Advanced Basal Cell Carcinoma

Interferon Gamma in Treating Patients With Recurrent or Metastatic Melanoma or Other Solid Tumors

Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and Sézary Syndrome and Advanced Synovial Sarcoma

Vaccine Therapy Followed by Biological Therapy in Treating Patients With Stage III or Stage IV Melanoma

Long-Term Safety Extension Study of ACTIMMUNE® (Interferon γ-1b) in Children and Young Adults With Friedreich's Ataxia

Topical Interferon Gamma-1b for Central Serous Chorioretinopathy

The Effects of r-metHuIFN-Gamma on the Lungs of Patients With AIDS